Status:
UNKNOWN
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-70 years
Brief Summary
Background: Rebound acid hypersecretion and acid-related symptoms after discontinuation of proton-pump inhibitor has been reported in previous studies. In patients with concurrent gastro-esophageal re...
Detailed Description
Background: Rebound acid hypersecretion and acid-related symptoms after discontinuation of proton-pump inhibitor has been reported in previous studies. In patients with concurrent gastro-esophageal re...
Eligibility Criteria
Inclusion
- Patients with typical reflux symptoms (heartburn and/or acid regurgitation) validated by standard questionnaire GerdQ.16
- Aged from 18 to 70 years old.
- Willing to receive H. pylori eradication therapy.
Exclusion
- Symptomatic reflux patients with high grade erosive esophagitis ( Los Angeles classification Grade C and D) or Barrett's esophagus documented by endoscopy.
- Symptomatic reflux patients with a history of using PPI in recent one month.
- Subjects with known allergy to PPI.
- Peptic ulcer disease
- Cancers of the esophagus, stomach, and duodenum
- Esophageal or gastric varices
- Active upper gastrointestinal bleeding within 7 days prior to enrollment
- Status after total or subtotal gastrectomy
- Pregnancy
- Use of anticoagulants or antiplatelets within one week prior to enrollment
- Subjects with bleeding tendency
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2012
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01249482
Start Date
September 1 2010
End Date
August 1 2012
Last Update
December 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, Taiwan, 100